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Clinical assessment of the response to antiangiogenic therapy has been cumbersome. A study in 
this issue of Cancer Cell demonstrates that a combination of magnetic resonance imaging (MRI) 
for quantification of normalized vessels with measurements of circulating levels of proangiogenic 
factors, including FGF2, SDF1, and viable circulating endothelial cells, provides an effective means 
to evaluate the response of recurrent glioblastoma to a prototypical pan-VEGF receptor tyrosine 
kinase inhibitor, AZD2171.Glioblastoma  (GBM)  is  one  of  the 
most frequent malignant brain tumors 
in adults and has a poor response to 
chemotherapy  and  radiation.  Treat-
ment  of  newly  diagnosed  GBMs 
with  conventional  chemotherapeutic 
agents,  such  as  temozolomide  and 
radiation,  results  in  partial  response 
and  a  median  survival  of  12–14 
months. Moreover, conventional ther-
apy  of  recurrent  GBM  is  associated 
with  poor  outcomes,  with  less  than 
10% of patients having progression-
free  survival  at  6  months.  Recently, 
it  has  been  shown  that  coexpres-
sion  of  a  constitutively  active  vari-
ant  of  EGFR,  EGFRvIII,  and  PTEN 
confers  sensitivity  of  GBM  to  EGFR 
tyrosine-kinase  inhibitors  (Melling-




response  to  temozolomide  (Hegi  et 
al.,  2005).  However,  despite  all  of 
these interventions, all GBM patients 
relapse  and  succumb  to  tumor  pro-
gression.
GBMs  are  known  to  be  driven  by 
hypoxia  and  VEGF-A  overexpres-
sion.  Moreover,  the  vasculature  of 
GBMs  is  atypical,  disorganized,  and 
leaky,  resulting  in  the  generation  of 
vasogenic  brain  edema.  Therefore, 
defining  the  mechanism  by  which 
antiangiogenic  intervention  may  tar-





antiangiogenic  agents  in  the  treat-
ment  of  GBMs,  but  the  application 




ular  approaches,  Rakesh  Jain  and 
colleagues  have  demonstrated  that 
antiangiogenic agents through selec-
tive pruning and maturation of unsta-
ble  vessels  promote  the  emergence 
of  “normalized,”  pericyte-coated 




the  hope  that  judicious  introduction 




elor  et  al.  provide  evidence  for  nor-
malization  of  GBM  blood  vessels  in 
patients  treated  with  a  pan-VEGF 
receptor  tyrosine  kinase  inhibitor, 
AZD2171, in a phase 2 study (Batch-
elor  et  al.,  2007).  The  rationale  for 
using  AZD2171  was  based  partially 
on  results  showing  a  decrease  in 
perfusion  and  vessel  density  in  an 
in  vivo  breast  cancer  model  (Miller 
et al., 2006)  . Furthermore, using an lsevier Inc.orthotopic  glioma  model,  Jain  and 
colleagues  had  previously  identified 
the optimal window of time to deliver 














echo,  and  contrast  enhancement  to 
measure blood volume,  relative ves-
sel  size,  and  vascular  permeability 
and  concluded  that  AZD2171  was 
more  effective  in  pruning  large  size 
than  small  microvessels.  Further-
more, using defined magnetic  imag-
ing  parameters  ktrans  and  extracellu-
lar-extravascular volume  fraction  the 
authors demonstrated  that sculpting 
of  the  large  and  leaky  vessels  was 
associated  with  decreased  vascular 
permeability,  which  persisted  much 
longer  than  the  changes  in  relative 
vessel size. These data are in agree-
ment  with  reduced  vasogenic  brain 
edema as detected by MRI in patients 
with  malignant  brain  tumors  treated 
with  bevacizumab,  a  neutralizing 
antibody  to  VEGF-A,  together  with 
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Previewschemotherapy  (Pope  et  al.,  2006). 
Reduction of vasogenic brain edema 
during  AZD2171  treatment  allowed 
elimination  or  reduction  of  cortico-
steroids,  the chronic use of which  is 








ferentially  pruned  and  eliminated 





MRI  technology,  there  are  several 
factors that limit precise assessment 
of truly normalized vessels. First, the 
determination  of  a  “normalization 
window”  by  this  group  has  hereto-
fore been made in xenograft models 
using  direct  measurements  of  ves-
sel  size,  density,  and  permeability 
by  intravital  microscopy  (Winkler  et 
al.,  2004).  In  the  current  paper,  the 
evaluation  of  glioma  vessel  normal-
ization  relied  upon  the  evaluation  of 
relative  vessel  size  and permeability 
using  MRI,  as  serial  biopsy  could 
not be performed on  these patients. 
Second, MRI determination of vessel 
size  has  previously  been  performed 
only  in  animal  tumor  models  using 
optimal contrast agents and has not 
been validated in human tumors, and 




in  this  study  necessarily  relies  on 
“first  pass”  dynamic  measurements 
of  magnetic  susceptibility,  which 
would  be  subject  to  the  leakage  of 
this  agent  across  the  blood-tumor 
barrier and would threaten the accu-
racy of perfusion estimations, which 
depend  on  compartmentalization  of 
the contrast within the vessels (Den-
nie et al., 1998; Pathak et al., 2001). 
Vessel  size determinations  in  animal 
tumors typically have been done with 
larger-contrast molecules, like MION, 
which  can  equilibrate  in  the  blood 
but are yet to be approved for human 
use (Dennie et al., 1998; Pathak et al., 2001).  Other  factors  degrading  the 
accuracy of vessel size determination 
might  include  vessel  tortuosity  and 
disturbances as well as regional vari-
ations in brain tumor blood flow (Cha, 
2003).  Obviously,  if  vessel  size  and 
permeability  measurements  can  be 
validated and standardized, perhaps 
with larger-molecular-weight contrast 
agents,  these  measurements  might 
become  reliable  surrogate  markers 
for  assessing  the  response  of  glio-
mas to antiangiogenic agents.
Given  the  limitations  enumerated 
above, the authors took advantage of 
other surrogate biomarkers of neoan-
giogenesis,  including  plasma  levels 
of  FGF2,  SDF1,  and  viable  circulat-





and  FGF2,  while  progression  after 
drug  interruptions  correlated  with 
increases  in  circulating  progenitor 
cells  (CPCs)  and  plasma  FGF2  lev-
els (Figure 1). The increase in plasma 
levels  of  SDF1  and  FGF2  correlated 
with  the  MRI  measurements,  dem-
onstrating an  increase  in  the relative 
vessel  density  and  size.  Thus,  MRI 
determination  of  vessel  normaliza-
tion  in  combination  with  circulating 




for  evaluating  antiangiogenic  agents 
for the treatment of GBMs.
One  other  issue  that  requires  fur-
ther experimentation is that AZD2171 
blocks not only VEGFR tyrosine kinase 
activity  in  tumor  blood  vessels  but 
also other tyrosine kinases, including 
c-Kit, PDGFRα, and PDGFRβ, that are 







the  tumor  cells.  Understanding  the 
molecular target of AZD2171 may be 
critical for diminishing the end-organ 
toxicity  of AZD2171  if  this  agent will 
ultimately  be  used  in  combination 
with radiotherapy or chemotherapeu-
tic agents to determine whether there 
is  an  impact  on  survival  of  patients 
with GBM.  Indeed,  in  order  to  capi-
Figure 1. Assessment of Response to Antiangiogenic Therapy with AZD2171 by 



















Lastly,  one  paradox  of  antiangio-




tumor  vessels,  while  selecting  for 
maintenance  of  stabilized  vessels 
that are believed to efficiently deliver 
oxygen,  nutrients,  and  chemothera-
peutic  agents  to  the  tumors.  How-




vessels  is unlikely  to  result  in a cure 
or  durable  remission;  thus,  target-  Cancer Cell 11, January 2007 ©2007 Eing stable tumor vessels may also be 
necessary. As such, development of 
effective  cytotoxic  therapies  and/or 
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